Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00960245

Enrollment

Registered

2009-08-17

Start date

1994-07-31

Completion date

1994-07-31

Last updated

2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Blood Pressure, Migraine Headaches, Chest Pain

Brief summary

The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.

Interventions

DRUGNadolol (1 x 80 mg) Tablets (Invamed, Inc)

DRUGCorgard (1 x 80 mg) Tablets (Bristol Laboratories)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

* Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.

Design outcomes

Primary

Measure	Time frame
Bioequivalence based on AUC and Cmax	21 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026